Related Experiment Videos

Serum CD95 of relapsing remitting multiple sclerosis patients protects from CD95-mediated apoptosis

F Zipp1, K Otzelberger, J Dichgans

  • 1Department of Neurology, University of Tübingen, Germany. frauke.zipp@uni-tuebingen.de

Insights

Serum from multiple sclerosis patients contains inhibitors that block T cell death. This may contribute to prolonged immune responses in multiple sclerosis (MS) by preventing normal regulation of T cell expansion.

Area of Science:

  • Immunology
  • Neuroimmunology
  • Autoimmunity

Background:

  • T cell apoptosis, regulated by CD95, is crucial for controlling immune responses.
  • Dysregulation of T cell apoptosis is implicated in autoimmune diseases like multiple sclerosis (MS).
  • Elevated levels of soluble CD95 have been observed in MS patients with active disease.

Purpose of the Study:

  • To investigate the potential role of serum factors in inhibiting CD95-mediated apoptosis in MS.
  • To determine if serum CD95 levels correlate with the inhibitory activity on T cell apoptosis.

Main Methods:

  • Analysis of sera from multiple sclerosis patients.
  • Assay to measure CD95 ligand-induced apoptosis in susceptible target cells.
  • Quantification of soluble CD95 levels in patient sera.

Main Results:

  • Sera from MS patients demonstrated a concentration-dependent inhibition of CD95 ligand-induced apoptosis.
  • The inhibitory effect of MS sera on apoptosis was directly related to the levels of soluble CD95 present.
  • These findings indicate the presence of biologically active inhibitors of T cell apoptosis in MS sera.

Conclusions:

  • Serum from MS patients contains active inhibitors of T cell apoptosis.
  • These inhibitors, associated with soluble CD95 levels, may contribute to aberrant T cell expansion in MS.
  • This mechanism could play a role in the pathogenesis of T cell-mediated autoimmune diseases like multiple sclerosis.

Related Concept Videos